tuneTypical Dose
formulation-specific
Microbiome Modulator
Synbiotics
Probiotic + prebiotic combination
Evidence TierBWADA NOT PROHIBITED
watchEffect Window
Weeks to months.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Synbiotics combine probiotics and prebiotics to support gut and metabolic outcomes.
They can improve selected constipation, IBS, and glycemic endpoints in some trials, but effects depend on the exact strain-plus-substrate pairing. Use evidence-matched combinations and track a single primary outcome.
Combined microbiome-modulating strategy that can improve gut and metabolic markers when strain/substrate pairing is appropriate.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- IBS/constipation symptom support
- Modest glycemic improvement in prediabetes/T2D
- NAFLD biomarker support
Secondary Outcomes
- Formulation-specific response variability
Safety
Contraindications and Interactions
Contraindications
- Severe immunocompromised states without clinician oversight
Side effects
- Gas/bloating
- Stool pattern changes
Interactions
- No major class-wide interactions; monitor in complex medical regimens
Avoid if
- No product transparency or no outcome-tracking plan
Evidence
Study-level References
synbiotics-SRC-001Systematic review and network meta-analysis.
Sourceopen_in_newWu Y, et al. The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-analysis. Nutrients. 2024;16(13):2114. doi:10.3390/nu16132114. PMID:38999862.
Key findings: Supports symptom improvement with heterogeneity.
Paper content
Supports symptom improvement with heterogeneity.
synbiotics-SRC-002Systematic review and meta-analysis.
Sourceopen_in_newFord AC, et al. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044-1060. doi:10.1111/apt.15001. PMID:30294792.
Population: IBS RCTs across multiple microbiome interventions.
Dose protocol: Mixed regimens; relatively sparse prebiotic data.
Key findings: Favorable pooled effect for microbiome-targeted strategies.
Paper content
Insufficient prebiotic evidence for definitive IBS efficacy conclusions.
synbiotics-SRC-003Systematic review and meta-analysis of RCTs.
Sourceopen_in_newvan der Schoot A, et al. Probiotics and synbiotics in chronic constipation in adults: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2022;41(12):2759-2777. doi:10.1016/j.clnu.2022.10.015. PMID:36372047.
Key findings: Modest constipation-related benefit.
Paper content
Modest constipation-related benefit.
synbiotics-SRC-004Systematic review and meta-analysis.
Sourceopen_in_newBaroni I, et al. Probiotics and synbiotics for glycemic control in diabetes: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2024;43(4):1041-1061. doi:10.1016/j.clnu.2024.03.006. PMID:38527396.
Key findings: Modest glycemic improvements.
Paper content
Modest glycemic improvements.
synbiotics-SRC-005GRADE-assessed systematic review and meta-analysis.
Sourceopen_in_newNaseri K, et al. Probiotics and synbiotics supplementation improve glycemic control parameters in subjects with prediabetes and type 2 diabetes mellitus: A GRADE-assessed systematic review, meta-analysis, and meta-regression. Pharmacol Res. 2022;184:106399. doi:10.1016/j.phrs.2022.106399. PMID:35987483.
Key findings: Consistent favorable glycemic trend.
Paper content
Consistent favorable glycemic trend.
synbiotics-SRC-006Systematic review and meta-analysis.
Sourceopen_in_newCai J, et al. The effect of synbiotics in patients with NAFLD: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2023;16:17562848231174299. doi:10.1177/17562848231174299. PMID:37388120.
Key findings: Beneficial NAFLD-related biochemical effects.
Paper content
Beneficial NAFLD-related biochemical effects.
synbiotics-SRC-007Systematic review and meta-analysis of RCTs.
Sourceopen_in_newMusazadeh V, et al. The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with NAFLD: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2024;208:107398. doi:10.1016/j.phrs.2024.107398. PMID:39241935.
Key findings: Broad modest improvements across NAFLD cardiometabolic markers.
Paper content
Broad modest improvements across NAFLD cardiometabolic markers.
synbiotics-SRC-008Systematic review and meta-analysis of 26 randomized controlled trials.
Sourceopen_in_newYin T, Lai L, Lin X, et al. Gut microbiota, a new approach to management of polycystic ovary syndrome: a systematic review, meta-analysis and meta-evidence of 26 randomized controlled trials. J Ovarian Res. 2026;18. doi:10.1186/s13048-025-01959-x. PMID:41776555.
Population: Women with PCOS aged 25 to 29 years across 26 RCTs.
Dose protocol: Probiotic, prebiotic, or synbiotic supplementation for 8 to 24 weeks in women with PCOS
Key findings: Synbiotics reduced weight (SMD -0.57), insulin (SMD -0.60), total testosterone (SMD -1.47), and improved HDL and antioxidant capacity across 26 pooled RCTs.
Notes: Extends synbiotic evidence into reproductive endocrine health (PCOS).
Paper content
This 2026 meta-analysis pooled 26 RCTs evaluating probiotics, prebiotics, and synbiotics in women with PCOS. Synbiotics and related microbiome interventions significantly reduced weight, BMI, waist circumference, insulin, HOMA-IR, triglycerides, and total testosterone. They also increased HDL cholesterol and antioxidant capacity. The testosterone reduction (SMD -1.47) is notable for PCOS management. This study extends the synbiotic evidence base into reproductive endocrine health, supporting the broader theme that gut microbiome modulation can produce metabolic and hormonal benefits in metabolically dysregulated populations.
synbiotics-SRC-009Systematic review with murine meta-analysis and narrative review of 6 human trials.
Sourceopen_in_newBonnard LC, Sharpe GR, Martin M, Dodd GF, Williams NC. Prebiotics and synbiotics in asthma: an integrative review of human trials and murine meta-analysis. Nutrients. 2026;18(4):683. doi:10.3390/nu18040683. PMID:41754200.
Population: 17 studies total (11 murine, 6 human intervention trials) examining prebiotic and synbiotic effects on asthma outcomes.
Dose protocol: Prebiotic and synbiotic interventions for asthma across 6 human trials and 11 murine studies
Key findings: Murine meta-analysis showed reduced airway hyperresponsiveness and type 2 cytokines. Human trials showed improvements in lung function and asthma control.
Notes: Human evidence still limited. Extends the synbiotic application space to respiratory immune modulation.
Paper content
This 2026 integrative review combined a meta-analysis of 11 murine studies with a narrative review of 6 human intervention trials examining prebiotics and synbiotics for asthma. Murine meta-analysis showed significant reductions in airway hyperresponsiveness and type 2 cytokines (IL-4, IL-5, IL-13). Human trials showed improvements in lung function, asthma control, and inflammatory markers. The authors conclude that prebiotics and synbiotics may serve as adjunct treatments for asthma but acknowledge that the human evidence base is still small and that well-controlled RCTs are needed. This is relevant to the synbiotic evidence profile as it extends the potential application space beyond gut and metabolic outcomes into respiratory immune modulation.